

HPTN at HIV R4P Virtual 20201

Study/Abstract #	Title	Presenter	Type	When
HPTN 073				
PE01.30	Identifying sexual risk profiles and PrEP initiation among Black sexual minority men in HPTN 073	Derek Dangerfield II	Poster	On Demand
HPTN 082				
PE01.38	Assessing Longitudinal Patterns of Depressive Symptoms and the Influence of Symptom Trajectories on PrEP Persistence Among Adolescent Girls in HPTN 082	Jennifer Velloza	Poster	On Demand
PE18.02	Predicting PrEP efficacy in women with partial adherence to tenofovir and emtricitabine	James Moore	Poster	On Demand
PE25.06	PrEP Adherence is Associated With Periods of HIV Risk Among Adolescent Girls and Young Women in South Africa and Zimbabwe	Jennifer Velloza	Poster	On Demand
HPTN 084				
HY01.02	Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084	Sinead Delany-Moretlwe	Oral	Wednesday 27 January, 15:15 (UTC)/10:15 (EST)
AMP				
HY01.01	VRC01 antibody prevention of HIV	Lawrence Corey	Oral	Wednesday 27 January, 15:00 (UTC)/10:00 (EST)
OA03.03	Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)	Nonhlanhla N. Mkhize	Oral	Wednesday 27 January, 17:46 (UTC)/12:46 (EST)
OA03.04LB	Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)	Carolyn Williamson	Oral	Wednesday 27 January, 17:54 (UTC)/12:54 (EST)
HVTN 127/HPTN 087				
OA03.01	Safety and Single-Dose Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses	Stephen Walsh	Oral	Wednesday 27 January, 17:30 (UTC)/12:30 (EST)
HPTN Modelling Center				

PE16.04	Assessing the use of surveillance data to estimate reductions in HIV incidence achieved by combination HIV prevention programs: a mathematical modelling study	Kate Mitchell	Poster	On Demand
PE18.01	Estimating the impact of PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir/emtricitabine among men who have sex with men in the United States: mathematical modelling for HPTN 083	Kate Mitchell	Poster	On Demand
PE07.01	COVID-19 and associated disruptions may indirectly affect HIV outcomes in two capital cities in Western/Central Africa: a modelling study	Romain Silhol	Poster	On Demand
HPTN 071				
	Understanding and unpacking the results of the HPTN 071 (PopART) trial		Satellite	Thursday 04 February, 12:15 - 13:45 (UTC)/ 7:15 – 8:45 (EST)
	Introduction: Overview of trial and results	Helen Ayles		12:15 (UTC)/ 7:15 (EST)
	Did the PopART intervention lead to changes in sexual behavior? Were there differences in behavior between study arms?	Ethan Wilson		12:20 (UTC)/ 7:20 (EST)
	Model projections: Did the mathematical model fit the data from the trial? What was the projected impact of the intervention if sustained over time and implemented more widely?	William Probert		12:35 (UTC)/ 7:35 (EST)
	How did ART adherence and viral suppression in those on ART compare between study arms and over time? Could poor adherence explain the lower impact in Arm A?	David Macleod		12:50 (UTC)/ 7:50 (EST)
	What were the community-level correlates of HIV incidence in the trial? Could differences in community viral burden explain the differences in incidence between study arms and between communities?	Timothy Skalland		13:05 (UTC)/ 8:05 (EST)
	Summary and concluding remarks	Richard Hayes		13:20 (UTC)/ 8:20 (EST)